Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

Designer self‐assembling peptides form the entangled nanofiber networks in hydrogels by
ionic‐complementary self‐assembly. This type of hydrogel has realistic biological and …

Ovarian cancer (OC) is the leading cause of death of gynecological malignancy.
Sonodynamic therapy (SDT) with high penetration ability and minimal invasion is …

The estrogen receptor (ER) has functionality in selected ovarian cancer subtypes and
represents a potential target for therapy. The majority (> 80%) of high grade serous, low …

The standard treatment of ovarian cancer (OC) patients, including debulking surgery and
first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority …

Ovarian cancer (OC) remains the leading cause of mortality due to gynecological
malignancies. Epidemiological studies have demonstrated that steroid hormones released …

Venous thromboembolism (VTE) is a major health problem in patients with cancer. Cancer
augments thrombosis and causes cancer-associated thrombosis (CAT) and vice versa …

Background: Ovarian cancer (OC) is one of the most malignant tumors in the female
reproductive system, with a poor prognosis. Various responses to treatments including …

Objective We describe a phase II clinical trial of the combination of ribociclib and letrozole
for treatment of relapsed oestrogen receptor (ER)-positive ovarian cancer (OC) and …

Purpose: Insulin-like growth factor 1 (IGF1) signaling regulates breast cancer initiation and
progression and associated cancer phenotypes. We previously identified E-cadherin …